Precision Cancer Diagnostics
Precision Cancer Diagnostics
Geneseq Biosciences designs, validates, and launches pioneering genomic cancer tests, distributed globally through licensing and partnerships.
NATA-accredited microRNA classifier that provides standardized, objective molecular assessment to complement histopathology in melanocytic lesion diagnosis. Reduces diagnostic variability and supports confident clinical decision-making.
World-first NATA-accredited melanoma blood test using microRNA profiling. Provides non-invasive molecular risk assessment from a simple blood draw—enabling early detection, treatment monitoring, and ongoing surveillance.
Toolkit for transforming histopathology reports into prognostic assessments, including diagnostic ambiguity detection and strategic treatment summaries.
Larger, multi-indication diagnostic assay, building on patented Melaseq technology.
Scalable next-generation microRNA analysis platform for early cancer detection, with class-leading accuracy and data transparency, at a price point that enables broad access.
| Year | Title | Journal | Link |
|---|---|---|---|
| 2024 | RNA-seq validation of microRNA expression signatures for precision melanoma diagnosis and prognostic stratification | BMC Medical Genomics | View |
| 2023 | Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma | British Journal of Dermatology | View |
| 2023 | Liquid biopsy test for Australia’s National Cancer, clinical validation poster | AACR Annual Meeting | View |
| 2021 | Translation of a circulating miRNA signature of melanoma to tissue | Biomarkers in Medicine | View |
| 2019 | Characterisation and validation of Mel38; a multi-tissue microRNA signature of cutaneous melanoma | PLOS ONE | View |
| 2018 | Circulating microRNA biomarkers in melanoma | Biomolecules | View |
| 2019 | A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response | Melanoma Research | View |
| 2018 | Development and validation of a plasma-based melanoma biomarker (MEL38) | British Journal of Cancer | View |
Family of patents protecting core microRNA diagnostic technology.
Australia
Japan
United States
South Korea
Europe
Canada
ChinaSource: WO2019068139A1 and national phase entries.
Geneseq is a Melbourne-based genomics company focused on microRNA diagnostics for cancer. We combine international experience in IVD assay design, with scalable bioinformatics, and regulatory know-how to turn ideas into clinically actionable results.
